导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.06% | 2834/4773 |
| 近一周 | -2.14% | 1313/5462 |
| 近一月 | -4.14% | 2252/5421 |
| 近一季 | -7.47% | 2413/5209 |
| 近半年 | -2.76% | 2009/4920 |
| 近一年 | 0.06% | 2641/4366 |
| 近两年 | 43.63% | 1701/2954 |
| 近三年 | 26.85% | 1191/2253 |
| 成立以来 | 44.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.54% 3271/4961 |
11.78% 2296/5312 |
- - |
- - |
| 2025 | 19.03% 2257/4813 |
-0.92% 2468/3635 |
2.21% 1761/4076 |
17.64% 2460/4524 |
-0.08% 2351/4813 |
| 2024 | 16.69% 778/3463 |
2.88% 679/2808 |
-1.15% 953/3014 |
16.39% 1469/3129 |
-1.42% 1695/3463 |
| 2023 | -8.60% 1032/2656 |
4.22% 1015/2280 |
-3.86% 933/2385 |
-2.64% 708/2515 |
-6.30% 1712/2655 |
| 2022 | -18.88% 769/2207 |
-13.67% 809/1919 |
6.68% 632/2016 |
-13.30% 875/2113 |
1.59% 1212/2208 |
| 2021 | 1.82% 654/1822 |
-2.40% 634/1255 |
6.43% 749/1330 |
-3.72% 657/1466 |
1.80% 795/1822 |
| 2020 | 35.28% 420/1250 |
-10.12% 758/1028 |
13.17% 644/1067 |
15.96% 182/1164 |
14.70% 257/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 民生加银沪深300ETF联接C VS. 长安沪深300非周期A(740101) |